Ocuphire Pharma Investor Day Presentation Deck

G 113 Overall Highlights from Ocuphire Investor R&D Day NyxolⓇ Nyxol® eye drops, as a platform, is uniquely positioned to address growing markets in refractive disorders Nyxol, if approved in 2023, would be the only Rx drop for reversing dilations and positively impact the patient experience in an eye care practice Nyxol represents a novel class with a differentiated MOA and potential as a convenient single evening drop with efficacy at 12 hours (and 18 hours) in the large presbyopia market Ocuphire plans to pursue both Nyxol as a single agent and with low dose pilocarpine as adjunctive therapy to treat a breadth of presbyopia patient types → more details to follow APX3330 The well-controlled, multi-center Phase 2b ZETA-1 for APX3330 is ~70% enrolled APX3330 new interim masked safety data support favorable safety profile as a potential oral treatment for diabetics with DR/DME APX3330 oral with dual MOA targeting VEGF and inflammation may be well-suited to reduce treatment burden and/or improve outcomes adjunctive to traditional anti-VEGF intravitreal injections across retinal diseases ** Ocuphire PHARMA

View entire presentation